MCID: INF009
MIFTS: 31

Inflammatory Spondylopathy

Categories: Bone diseases

Aliases & Classifications for Inflammatory Spondylopathy

MalaCards integrated aliases for Inflammatory Spondylopathy:

Name: Inflammatory Spondylopathy 12 15
Inflammatory Spondylopathies in Disease Classified Elsewhere 12
Inflammatory Spondylopathy in Disease Classified Elsewhere 12
Inflammatory Spondylopathies in Disease Ec 12
Spondylitis 71

Classifications:



External Ids:

Disease Ontology 12 DOID:12105
ICD9CM 34 720.81
ICD10 32 M46.8 M46.9
UMLS 71 C0021396 C0038012

Summaries for Inflammatory Spondylopathy

MalaCards based summary : Inflammatory Spondylopathy, also known as inflammatory spondylopathies in disease classified elsewhere, is related to discitis and spondylitis, and has symptoms including sciatica An important gene associated with Inflammatory Spondylopathy is LINC00523 (Long Intergenic Non-Protein Coding RNA 523). The drugs Indomethacin and Loxoprofen have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and testes.

Related Diseases for Inflammatory Spondylopathy

Diseases related to Inflammatory Spondylopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 2, show less)
# Related Disease Score Top Affiliating Genes
1 discitis 10.4
2 spondylitis 10.4

Symptoms & Phenotypes for Inflammatory Spondylopathy

UMLS symptoms related to Inflammatory Spondylopathy:


sciatica

Drugs & Therapeutics for Inflammatory Spondylopathy

Drugs for Inflammatory Spondylopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 155, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
2
Loxoprofen Approved Phase 4 68767-14-6, 80382-23-6 3965
3
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
4
Aceclofenac Approved, Investigational Phase 4 89796-99-6
5
Pamidronate Approved Phase 4 40391-99-9 4674
6
carbamide peroxide Approved Phase 4 124-43-6
7
Sulfasalazine Approved Phase 4 599-79-1 5353980 5359476
8
Hydroxychloroquine Approved Phase 4 118-42-3 3652
9
Etanercept Approved, Investigational Phase 4 185243-69-0
10
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
11
Acetaminophen Approved Phase 4 103-90-2 1983
12
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
13 Natriuretic Peptide, Brain Phase 4
14 Tocolytic Agents Phase 4
15 Tripterygium Phase 4
16 Mitogens Phase 4
17 Endothelial Growth Factors Phase 4
18 Cholestyramine Resin Phase 4
19 Antibodies, Monoclonal Phase 4
20 Cyclooxygenase 2 Inhibitors Phase 4
21 Antiprotozoal Agents Phase 4
22 Antiparasitic Agents Phase 4
23 Antimalarials Phase 4
24 Anti-Inflammatory Agents, Non-Steroidal Phase 4
25 Analgesics, Non-Narcotic Phase 4
26 Analgesics Phase 4
27 Cyclooxygenase Inhibitors Phase 4
28 Narcotics Phase 4
29 Antipyretics Phase 4
30 Analgesics, Opioid Phase 4
31
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
32
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
33
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
34 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
35
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
36
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
37
Certolizumab pegol Approved Phase 3 428863-50-7
38
Etoricoxib Approved, Investigational Phase 3 202409-33-4 123619
39
Misoprostol Approved Phase 3 59122-46-2 5282381
40
Apremilast Approved, Investigational Phase 3 608141-41-9 11561674
41 Brodalumab Approved, Investigational Phase 3 1174395-19-7
42
Esomeprazole Approved, Investigational Phase 3 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
43
Tofacitinib Approved, Investigational Phase 2, Phase 3 477600-75-2
44
Upadacitinib Approved, Investigational Phase 3 1310726-60-3 58557659
45
tannic acid Approved Phase 3 1401-55-4
46
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
47
Ustekinumab Approved, Investigational Phase 3 815610-63-0
48
Entecavir Approved, Investigational Phase 3 142217-69-4 153941
49
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
50
Rebamipide Investigational Phase 3 90098-04-7
51 Methylprednisolone Acetate Phase 2, Phase 3
52 Hormone Antagonists Phase 2, Phase 3
53 Antineoplastic Agents, Hormonal Phase 2, Phase 3
54 glucocorticoids Phase 2, Phase 3
55 Antineoplastic Agents, Immunological Phase 2, Phase 3
56 Immunoglobulins Phase 3
57 Antibodies Phase 3
58 Angiogenesis Inhibitors Phase 3
59 Protective Agents Phase 3
60 Proton Pump Inhibitors Phase 3
61 Pharmaceutical Solutions Phase 2, Phase 3
62 Antacids Phase 3
63 Antioxidants Phase 3
64 Anti-Ulcer Agents Phase 3
65 Protein Kinase Inhibitors Phase 2, Phase 3
66 Janus Kinase Inhibitors Phase 3
67 Anti-Infective Agents Phase 3
68 Antiviral Agents Phase 3
69
Abatacept Approved Phase 2 332348-12-6 10237
70
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
71
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
72
Tolnaftate Approved, Investigational, Vet_approved Phase 2 2398-96-1 5510
73
Olsalazine Approved Phase 2 15722-48-2
74
Risedronate Approved, Investigational Phase 2 105462-24-6 5245
75
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
76
Curcumin Approved, Experimental, Investigational Phase 2 458-37-7 969516
77
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
78
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
79
Meloxicam Approved, Vet_approved Phase 2 71125-38-7 54677470 5281106
80
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
81
Naproxen Approved, Vet_approved Phase 2 22204-53-1 1302 156391
82 Anti-Bacterial Agents Phase 2
83 Neuroprotective Agents Phase 2
84 Antiemetics Phase 2
85 Antibiotics, Antitubercular Phase 2
86 Adjuvants, Immunologic Phase 2
87 MF59 oil emulsion Phase 2
88 Hemagglutinins Phase 2
89 interferons Phase 2
90 Interferon-gamma Phase 2
91 Antifungal Agents Phase 2
92 Diphosphonates Phase 2
93 Vitamins Phase 2
94 Trace Elements Phase 2
95 Micronutrients Phase 2
96 Hematinics Phase 2
97 Nutrients Phase 2
98 Interleukin-2 Phase 2
99 Lubricant Eye Drops Phase 2
100 Ophthalmic Solutions Phase 2
101 Vaccines Phase 2
102
Hyaluronic acid Approved, Vet_approved Phase 1 9004-61-9 53477741
103 Immunoglobulins, Intravenous Phase 1
104 Myeloma Proteins Phase 1
105 Immunoglobulin G Phase 1
106 Paraproteins Phase 1
107
Guaifenesin Approved, Investigational, Vet_approved 93-14-1 3516
108
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757
109
Polyestradiol phosphate Approved 28014-46-2
110
Alendronate Approved 66376-36-1, 121268-17-5 2088
111
Penicillin G Approved, Vet_approved 61-33-6 5904
112
Aminocaproic acid Approved, Investigational 60-32-2 564
113
Becaplermin Approved, Investigational 165101-51-9
114
Parathyroid hormone Approved, Investigational 9002-64-6
115
Morphine Approved, Investigational 57-27-2 5288826
116
Lidocaine Approved, Vet_approved 137-58-6 3676
117
Triamcinolone Approved, Vet_approved 124-94-7 31307
118
Glucosamine Approved, Investigational 3416-24-8 439213
119
Ibuprofen Approved 15687-27-1 3672
120
Vitamin A Approved, Nutraceutical, Vet_approved 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
121
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
122
Imidacloprid Vet_approved 105827-78-9 86418
123 Muramidase
124 Antibodies, Antiphospholipid
125 Technetium Tc 99m Medronate
126 Methylene diphosphonate
127 Radiopharmaceuticals
128 Hormones
129 Chlorpheniramine, phenylpropanolamine drug combination
130 Estradiol 17 beta-cypionate
131 Estradiol 3-benzoate
132 Tin Fluorides
133 Retinol palmitate
134 retinol
135 Penicillin G Benzathine
136 Penicillin G Procaine
137 Antifibrinolytic Agents
138 Coagulants
139 Calciferol
140 Complement C3
141 Complement System Proteins
142 Complement C3d
143 Cola
144 Hemostatics
145 Hypolipidemic Agents
146 Hydroxymethylglutaryl-CoA Reductase Inhibitors
147 Anticholesteremic Agents
148 Lipid Regulating Agents
149 Rosuvastatin Calcium 147098-20-2
150 Calcium, Dietary
151 Triamcinolone diacetate
152 triamcinolone acetonide
153 Triamcinolone hexacetonide
154 Rheumatoid Factor
155
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(showing 446, show less)
# Name Status NCT ID Phase Drugs
1 Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry Unknown status NCT02492217 Phase 4 Adalimumab
2 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
3 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
4 Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
5 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
6 Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Unknown status NCT02313727 Phase 4 Pamidronate
7 A Prospective, Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center, Interventional Study to Compare Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
8 The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis Unknown status NCT02634541 Phase 4 Adalimumab
9 An Open-Label Multicentre Long-Term Extension Study of Etanercept in Ankylosing Spondylitis Completed NCT00444340 Phase 4 Enbrel (Etanercept)
10 Multicentre, Open-Labeled Study Of Etanercept In The Treatment Of Patients With Ankylosing Spondylitis Completed NCT00458185 Phase 4 etanercept
11 Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) Completed NCT01895764 Phase 4 Adalimumab;Methotrexate
12 A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis Completed NCT00420238 Phase 4 Etanercept (Enbrel)
13 An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis Completed NCT00410046 Phase 4 Enbrel (etanercept)
14 A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis Completed NCT00247962 Phase 4 etanercept;sulphasalazine (SSZ)
15 Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy Controls Completed NCT00778869 Phase 4
16 Effect of Methotrexate on the Relation Dose-effect of Infliximab in Ankylosing Spondylitis Completed NCT00507403 Phase 4 infliximab
17 Effect of Anti-TNF(Alpha)Treatment on Circulating Endothelial Progenitor Cells (EPCs) and Vascular Stiffness in AS Completed NCT01212653 Phase 4 Simponi
18 Sequential Application of Yisaipu® and Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Treating Mild-to-Moderate Ankylosing Spondylitis: the Mid-term Follow-up Result Completed NCT03411798 Phase 4 Yisaipu®
19 A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis Completed NCT00873730 Phase 4 etanercept;etanercept/placebo
20 A Clinical Trial About the Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis: a 12-week, Multi-center, Randomized, Double-blind, Active Drug and Placebo Compared Clinical Trial Completed NCT00953979 Phase 4 kunxian capsule
21 A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis Completed NCT02528201 Phase 4 Celecoxib 200 milligrams;Celecoxib 400 milligrams;diclofenac 50 milligrams
22 An Open Trial to Evaluate the Efficacy and Safety of Infliximab(Remicade) in Treating Patients With Early Ankylosing Spondylitis Completed NCT00936143 Phase 4 infliximab
23 Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot Study Completed NCT00779935 Phase 4
24 Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis Completed NCT00779012 Phase 4
25 Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy Completed NCT01517620 Phase 4 Total Glucosides Paeony Capsules
26 Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis: a Prospective, Randomized Multicentric Study on Disease Activity Guided Etanercept Tapering or Discontinuation Completed NCT03880968 Phase 4 tapering or discontinuation of etanercept
27 Efficacy and Safety of Loxoprofen Hydrogel Patch Versus Loxoprofen Tablet in Patients With Ankylosing Spondylitis: a 4-week Randomized, Open-label Study Completed NCT03800797 Phase 4 Loxoprofen sodium hydrogel patch;Loxoprofen sodium tablet
28 A MULTICENTER OPEN-LABEL STUDY OF ETANERCEPT WITHDRAWAL AND RETREATMENT IN SUBJECTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WHO ACHIEVED ADEQUATE 24 WEEK RESPONSE Completed NCT02509026 Phase 4
29 A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Completed NCT01934933 Phase 4 celebrex;Enbrel;Enbrel plus Celebrex
30 Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study Completed NCT03473665 Phase 4 Indomethacin;Diclofenac;Meloxicam;Celecoxib
31 The Efficacy of Combination Methotrexate and Infliximab in Patients With Ankylosing Spondylitis:A Clinical and Magnetic Resonance Imaging Correlation Completed NCT00432432 Phase 4 Infliximab and MTX
32 Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012 Completed NCT01668004 Phase 4
33 Chung Shan Medical University Hospital, Taiwan Completed NCT00647517 Phase 4 Ultracet
34 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
35 Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial Completed NCT01718951 Phase 4 golimumab;Pamidronate
36 A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the NSAID-sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis (ASTRUM) Completed NCT02763046 Phase 4 AIN457/Secukinumab Placebo; Biological: AIN457/Secukinumab
37 Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial Completed NCT00715091 Phase 4 diclophenac;diclophenac
38 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Three Years' Following-up Study Completed NCT02915354 Phase 4 Etanercept
39 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
40 Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Results From MRI Finding Completed NCT03190603 Phase 4 Celecoxib
41 Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial. Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
42 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Completed NCT02477150 Phase 4
43 Treatment of Active Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection: a Randomized, Double-blind, Multicentral Clinical Trial to Investigate the Efficacy and Safety of Yisaipu® Completed NCT02364479 Phase 4 50mg Yisaipu;25mg etanercept;Placebo
44 A Multicenter,Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis Recruiting NCT03932006 Phase 4 Fengshigutong Capsule plus Imrecoxib;Fengshigutong Capsule;Imrecoxib
45 A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg (ASLeap) Recruiting NCT03350815 Phase 4 150 mg open-label secukinumab;150 mg double-blinded secukinumab;300 mg double-blinded secukinumab
46 A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Recruiting NCT03733925 Phase 4 Golimumab
47 TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study) Recruiting NCT03639740 Phase 4 Secukinumab 150 milligram [Cosentyx]
48 GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC). Recruiting NCT02687724 Phase 4 Golimumab (GLM)
49 COmparison of the Effect of Treatment With NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine Over Two Years in Patients With ankyLosing Spondylitis: a Randomized Controlled Multicentre Trial Active, not recruiting NCT02758782 Phase 4 Celecoxib
50 Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study Not yet recruiting NCT04077957 Phase 4 Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept (50mg per week, for 4 weeks);Etanercept (50mg per week, for 2 weeks);Etanercept (50mg per week)
51 Prevention of Metacarpophalangeal Joints Structure Damage in Patients With Psoriatic Arthritis Using Secukinumab Not yet recruiting NCT03623867 Phase 4 Secukinumab;Placebo
52 Effects of Etanercept on Endothelial Function and Carotid Intima-media Thickness (IMT) in Patients With Active AS Terminated NCT00910273 Phase 4 etanercept
53 Study of Peripheral Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab Terminated NCT00686894 Phase 4 Infliximab
54 A Randomized Multicentre Clinical Trial Comparing The Metal on Metal Hip System Versus The Metal on Highly Crossed Linked Polyethylene System Terminated NCT01422564 Phase 4
55 A Study to Evaluate the Clinical Benefits of Tramadol/Acetaminophen (Ultracet®) vs. Diclofenac (Voltaren®) in the Treatment of Pain in Patients With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs) Terminated NCT00766402 Phase 4 Tramadol /acetaminophen;Diclofenac
56 Discontinuation of TNF-alpha Inhibitors in Spondylarthritis Patients With Low Disease Activity, and Re-initiation of Therapy if Disease Flares Terminated NCT00726804 Phase 4 Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)
57 Hip Arthritis Associated With AS Efficacy and Safety of Early Treatment With Infliximab (Remicade®) Withdrawn NCT01148901 Phase 4 Infliximab
58 Efficacy of Adalimumab (Humira®) in Spondyloarthritis Related to Crohn's Disease Withdrawn NCT00972218 Phase 4
59 Methotrexate in the Treatment of Axial Spondyloarthritis. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study. Withdrawn NCT00298012 Phase 4 Methotrexate
60 Clinical Study of Tripterygium Capsule to Treat Early Ankylosing Spondylitis: a 12-Week, Multiple Centers, Randomized Double-Blind, Positive Drug and Placebo Controlled Clinical Trial Unknown status NCT00889694 Phase 2, Phase 3 Tripterygium;Sulfasalazine;placebo
61 Threecenter Placebo Controlled Three Arm Trial in Patients With Active Ankylosing Spondylitis With Prednisolone Unknown status NCT00244166 Phase 2, Phase 3 prednisolone
62 Phase III Study of Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat AS Unknown status NCT02809781 Phase 2, Phase 3 Etanercept
63 Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis Unknown status NCT00432653 Phase 2, Phase 3 rituximab
64 Adalimumab in Early Axial Spondyloarthritis (Without Radiological Sacroiliitis): Placebo Controlled Phase Over 3 Months Followed by a 9 Months Open Extension Phase Unknown status NCT00235105 Phase 2, Phase 3 Adalimumab 40 mg sc every other week
65 A Phase 3, Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis Completed NCT00195819 Phase 3
66 Multicenter, Double-Blind, Parallel, Placebo-Controlled, Randomised Phase 3 Study of Etanercept in the Treatment of Patients With Ankylosing Spondylitis: 12-Week Final Data Completed NCT00421915 Phase 3 Enbrel (etanercept)
67 A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly Compared With 25 mg Twice Weekly in Subjects With Ankylosing Spondylitis Completed NCT00418548 Phase 3 Etanercept
68 International Multi-center Comparative Double-blind Randomized Clinical Trial to Evaluate Efficacy and Safety of BCD-055 (JSC "BIOCAD", Russia) and Remicade® in Patients With Ankylosing Spondylitis Completed NCT02762812 Phase 3
69 A Randomized, Open Label, 3-arm Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis Completed NCT02183168 Phase 3 Meloxicam suppository;Meloxicam tablet;Indomethacin
70 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the 16 Week Efficacy and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis Completed NCT01358175 Phase 3 Secukinumab (75 mg);Secukinumab (150 mg);Placebo
71 Open-label, Long-term Extension Study of Etanercept in the Treatment of Patients With Ankylosing Spondylitis Who Participated in Protocol 16.0037 Completed NCT00356356 Phase 3 Etanercept
72 A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial Parallel Controlled With Humira to Evaluate the Efficacy and Safety of BAT1406 Injection in the Treatment of Ankylosing Spondylitis Completed NCT04135508 Phase 3 BAT1406;Humira
73 A Phase 3 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis Completed NCT00085644 Phase 3
74 A 12-Week Symptomatic Effect Evaluation to Compare Celecoxib 200 mg QD, Celecoxib 200 mg BID and Diclofenac 75 mg SR BID in Patients With Ankylosing Spondylitis Completed NCT00648141 Phase 3 Celecoxib;Celecoxib;Diclofenac
75 A Randomized, Double-blind, Placebo-controlled Phase III Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy at 16 Weeks and to Assess Long-term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Ankylosing Spondylitis Completed NCT01649375 Phase 3 Secukinumab (75 mg);Placebo;Secukinumab (150 mg)
76 An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis Completed NCT00421980 Phase 3 Etanercept
77 A Randomized, Double-blind Trial of the Efficacy of REMICADE (Infliximab) Compared With Placebo in Subjects With Ankylosing Spondylitis Receiving Standard Anti-inflammatory Drug Therapy Completed NCT00207701 Phase 3 infliximab
78 A Multi-Center, Open-Label Efficacy, Safety, and Pharmacokinetic Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis Completed NCT00667355 Phase 3
79 A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis Completed NCT02008916 Phase 3 Secukinumab;Placebo secukinumab
80 A 6-Week, Randomized, Double-Blind, Parallel-Group Study To Evaluate The Symptomatic Effects And Safety Of Celecoxib 200mg QD Compared To Diclofenac 75mg SR QD In Chinese Patients With Ankylosing Spondylitis, With 6-Week Extension Phase Treatment On Celecoxib 400 Mg QD Or Maintaining Double-Blind Phase Therapy Completed NCT00762463 Phase 3 Celecoxib;Diclofenac SR
81 An Open-label, Phase III, Study of Subcutaneous Secukinumab to Assess Efficacy, Safety and Tolerability at up to 52 Weeks in Japanese Patients With Active Ankylosing Spondylitis Completed NCT02750592 Phase 3 Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.
82 Safety and Efficacy of Prefilled Liquid Etanercept(Yisaipu) for Active Ankylosing Spondylitis on the Basis of NSAID Therapy: A Multicenter Randomized, Double-blind, Parallel Group Phase III Trial Completed NCT04345458 Phase 3 prefilled liquid etanercept(Yisaipu);lyophilized etanercept powder(Yisaipu)
83 Study of Two Schedules of Infliximab Maintenance Therapy in Ankylosing Spondylitis: Comparison of Infusion Every 6 Weeks Versus Infusion on Demand Completed NCT00439283 Phase 3 infliximab;methotrexate
84 A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Study of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis Completed NCT01114880 Phase 3
85 Effects of Aerobic Training in Patients With Ankylosing Spondylitis Completed NCT01586650 Phase 3
86 Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis (AS) and Inadequate Response to ≥2 Nonsteroidal Antiinflammatory Drug (NSAID) Completed NCT01091675 Phase 3 Etoricoxib
87 A Phase III, Randomized, Double-dummy, Double Blind, Misoprostol-comparative Clinical Trial to Evaluate the Efficacy and Safety of Mucosta® Tablet in the Prevention of NSAID-induced Gastrointestinal Complications Completed NCT00576706 Phase 3 Rebamipide;Misoprostol
88 Infliximab as First Line Therapy in Patients With Early Active Axial Spondyloarthritis Trial Completed NCT00844805 Phase 3 Infliximab;Placebo;Naproxen
89 A Randomized, Double-blind, Placebo-controlled, Phase III Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes, to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Ankylosing Spondylitis Completed NCT02896127 Phase 3 Secukinumab;Placebo
90 Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis - An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY) Completed NCT00478660 Phase 3 adalimumab (Humira)
91 An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis Completed NCT01863732 Phase 3
92 A Multicenter, Randomized, Double-blind, Parallel-controlled Phase 3 Study Evaluating the Efficacy and Safety of Recombinant Human Monoclonal Antibody Against Human Tumor Necrosis Factor-α (IBI303) Compared to Adalimumab in Patients With Active Ankylosing Spondylitis Completed NCT02893254 Phase 3 IBI303;Adalimumab
93 A Study Investigating an Exercise and Education Programme for Individuals With Ankylosing Spondylitis. Completed NCT00764686 Phase 3
94 CANaDian Evaluation of Low DosE Infliximab in Ankylosing Spondylitis Completed NCT00202865 Phase 3
95 A Randomized, Double-blind, Placebo-controlled, Phase III Multicenter Study of Subcutaneous Secukinumab (150 mg) With and Without a Subcutaneous Loading Regimen to Assess Efficacy, Safety, and Tolerability up to 2 Years in Patients With Active Ankylosing Spondylitis Completed NCT02159053 Phase 3
96 A Multicenter, Open-label (Part A) Followed by a Randomized, Double-blind, Parallel-group, Placebo Controlled Study (Part B) to Evaluate Maintenance of Remission in Subjects With Active Axial Spondyloarthritis (axSpA) Receiving Either Certolizumab Pegol 200 mg Q2W or 200 mg Q4W as Compared to Placebo Completed NCT02505542 Phase 3
97 A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use of an Electro-Mechanical Injection Device (E-Device) for the Subcutaneous Self-Injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease Completed NCT03357471 Phase 3 e-Device
98 A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers. Completed NCT00367211 Phase 3 PN 200 tablets (500 mg naproxen and 20 mg omeprazole);Naproxen 500 mg tablets (PN 200 minus omeprazole)
99 A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis Completed NCT02186873 Phase 3 Placebo;Golimumab
100 Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase III Study of Etanercept in the Treatment of Subjects With Ankylosing Spondylitis Completed NCT00434044 Phase 3 Enbrel (etanercept)
101 A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Golimumab Administered Subcutaneously in Subjects With Active Axial Spondyloarthritis (Protocol No. P07642, Also Known as MK-8259-006-02). Completed NCT01453725 Phase 3
102 A Multicentre, 12 Week Double Blind Placebo Controlled Randomized Study Of Etanercept On A Background Nsaid In The Treatment Of Adult Subjects With Non Radiographic Axial Spondyloarthritis With A 92 Week Open Label Extension Completed NCT01258738 Phase 3 Background NSAID;Background NSAID
103 A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis Completed NCT02696798 Phase 3 Ixekizumab;Placebo
104 A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis Completed NCT01208207 Phase 3 Part I - etoricoxib 60 mg;Part I - etoricoxib 90 mg;Part I- naproxen 1000 mg;Part I - Placebo to naproxen 500 mg;Part II- etoricoxib 60 mg;Part II- etoricoxib 90 mg;Part II- naproxen 1000 mg;Part I - Placebo to etoricoxib 60 mg;Part I - Placebo to etoricoxib 90 mg;Part II- Placebo to etoricoxib 60 mg;Part II - Placebo to etoricoxib 90 mg;Part II- Placebo to naproxen 500 mg
105 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects With Ankylosing Spondylitis Completed NCT01248793 Phase 3 Placebo;Golimumab;Golimumab (placebo group)
106 A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS Completed NCT01583374 Phase 3 Apremilast tablet 20 mg;Apremilast tablet 30 mg BID;Placebo
107 A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalpha MonoclonalAntibody, Administered Subcutaneously, in Subjects With Active Ankylosing Spondylitis Completed NCT00265083 Phase 3
108 A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis Completed NCT01808118 Phase 3
109 A Double-blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis Completed NCT01166282 Phase 3
110 A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis Completed NCT02696785 Phase 3 Ixekizumab;Placebo;Adalimumab
111 A Prospective Double Blind Placebo Controlled Trial of Combination Disease Modifying Antirheumatic Drugs (DMARDs) vs Monotherapy (Sulfasalazine) in Patients With Inflammatory Low Backache in Early Seronegative Spondylarthropathy Completed NCT01040195 Phase 3 Methotrexate, Hydroxychloroquine;Placebo
112 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of KHK4827 in Subjects With Axial Spondyloarthritis Completed NCT02985983 Phase 3 KHK4827;Placebo
113 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis Completed NCT00939003 Phase 3
114 An Investigator Initiated, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Humira® (Adalimumab) For The Treatment of Interstitial Cystitis(IC) Completed NCT01295814 Phase 3 Adalimumab
115 Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis Completed NCT02497976 Phase 3 Placebo
116 A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 in Subjects Who Are at Risk for Developing NSAID-associated Ulcers Completed NCT00527904 Phase 3 PN400 (VIMOVO);PN 400 (VIMOVO)
117 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Peripheral Spondyloarthritis Completed NCT01064856 Phase 3
118 A 24-week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Secukinumab in Controlling Spinal Pain in Patients With Axial Spondyloarthritis Completed NCT03136861 Phase 3 AIN457 Placebo
119 A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis Completed NCT00035334 Phase 2, Phase 3 NC-503 (Anti-amyloidotic (AA) Agent)
120 Efficacy, Safety, and Tolerability of Infliximab (Remicade; Schering-Plough) in Juvenile Spondyloarthropathies: a Three-Month, Randomized, Double-Blind, Placebo-Controlled Trial and 52-Week Open Extension. Completed NCT00591201 Phase 2, Phase 3 infliximab;Placebo
121 A Phase III, Randomized, Double-blind, Placebo Controlled Multi-center Study of Subcutaneous Secukinumab (150 mg and 300 mg) in Prefilled Syringe to Demonstrate Efficacy (Including Inhibition of Structural Damage), Safety, and Tolerability up to 2 Years in Subjects With Active Psoriatic Arthritis (FUTURE 5) Completed NCT02404350 Phase 3
122 Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes Recruiting NCT02469753 Phase 3 NSAIDs;NSAIDs;anti-TNF
123 A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects With Axial Spondyloarthritis Recruiting NCT04169373 Phase 3 Upadacitinib;Placebo
124 A Multicenter, Randomized, Double-Blind and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Chinese Patients With Radiographic Axial Spondyloarthritis Recruiting NCT04285229 Phase 3 Ixekizumab;Placebo
125 A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Ankylosing Spondylitis or Non-radiographic Axial SpondyloArthritis Recruiting NCT04156620 Phase 3 Secukinumab;Placebo
126 Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial Recruiting NCT03738956 Phase 2, Phase 3 Tofacitinib
127 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS) Active, not recruiting NCT03502616 Phase 3 Tofacitinib
128 A Randomized, Partially-blinded Study of Secukinumab to Demonstrate Reduction of Radiographic Progression Versus GP2017 (Adalimumab Biosimilar) at 104 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis Active, not recruiting NCT03259074 Phase 3
129 An International, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of the Efficacy and Safety of BCD-085 (JSC BIOCAD, Russia) in Patients With Active Ankylosing Spondylitis Active, not recruiting NCT03447704 Phase 3 BCD-085
130 Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation Active, not recruiting NCT02552212 Phase 3
131 A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab. Active, not recruiting NCT03552276 Phase 2, Phase 3 tildrakizumab 200 mg (two 1-mL injections of 100 mg/mL);tildrakizumab 200 mg (two 1-mL injections of 100 mg/mL);tildrakizumab 100 mg (one 1-mL injection of 100 mg/mL + 1 mL placebo);tildrakizumab 200 mg (two 1-mL injections of 100 mg/mL)
132 A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs Active, not recruiting NCT02696031 Phase 3 Secukinumab;Placebo;Secukinumab;Secukinumab
133 A Multicenter, Open-Label Extension Study to Asses the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis Not yet recruiting NCT04436640 Phase 3 Bimekizumab
134 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis Suspended NCT03928743 Phase 3 Bimekizumab
135 A Randomized, Double-blind, Parallel Group Placebo-controlled Study of the Safety and Reduction of Signs and Symptoms During Treatment With Tocilizumab (TCZ) Versus Placebo in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous TNF Antagonist Therapy Terminated NCT01209689 Phase 3 Tocilizumab;Placebo
136 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis Terminated NCT02685904 Phase 3
137 A Ph II/III Seamless, Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Reduction in Signs and Symptoms and Inhibition of Structural Damage During Treatment With Tocilizumab Versus Placebo in Patients With Ankylosing Spondylitis Who Have Failed Non-steroidal Anti-inflammatory Drugs and Are naïve to TNF Antagonist Therapy NSAIDs Terminated NCT01209702 Phase 3 Placebo
138 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Nonradiographic Axial Spondyloarthritis Terminated NCT02407223 Phase 3 Group 1: Placebo;Group 2: Ustekinumab 45 mg;Group 3: Ustekinumab 90 mg
139 A Randomized, Double-blinded, Phase 3, Multicenter, Investigator-initiated Trial for Entecavir for Prophylaxis of Hepatitis B Virus (HBV) Reactivation in HBV Surface Antigen or Anti-HBc Positive Patients Undergoing Anti-TNFα Treatment Terminated NCT01694264 Phase 3 Entecavir;Placebo
140 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Subjects With Active Radiographic Axial Spondyloarthritis Terminated NCT02438787 Phase 3 Placebo;Ustekinumab 45 mg;Ustekinumab 90 mg;Golimumab 50 mg
141 Etoricoxibe - Preemptive and Postoperative Analgesia for Abdominal and Thoracic Surgery Terminated NCT00716833 Phase 3 Etoricoxibe;Placebo
142 A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Patients With Active Ankylosing Spondylitis Withdrawn NCT01870284 Phase 3 Ixekizumab;Placebo;Adalimumab
143 An Open-label Study of Etanercept (Enbrel) Efficacy in Ankylosing Spondylitis Unknown status NCT01289743 Phase 2 Etanercept
144 Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL) - a 12-week, Prospective, Open-label, Pilot Study Unknown status NCT01790022 Phase 2 Methylprednisolone
145 Open Study for the Evaluation of the Efficacy of Methotrexate 20mg Given Subcutaneously in Patients With Active Ankylosing Spondylitis Unknown status NCT00243750 Phase 2 Methotrexate
146 Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis—A Registry Project Unknown status NCT02456363 Phase 2 NSAIDs and sulfasalazine
147 Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis Unknown status NCT00558506 Phase 2 abatacept
148 Efficacy and Safety of Vaccination Against Influenza H1N1 in Patients With Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriatic Arthritis and Ankylosing Spondylitis Treated With Immunomodulatory Drugs Unknown status NCT01006681 Phase 2
149 New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis: Immunostimulation Plus Antibiotic Versus Immunosuppression Plus Antibiotic Versus Conventional Standardtherapy Unknown status NCT00244179 Phase 2 interferon-gamma;infliximab;dmard
150 Efficiency and Safety Study of Pamidronate in Inflammatory Back Pain Due to Degenerative Disk Disease Unknown status NCT01799616 Phase 2 Pamidronate
151 Randomized Controlled 12 Months Trial With Etanercept (Enbrel ®) vs. Sulfasalazine in Early Axial Spondyloarthritis With Focus on Improvement of Acute Inflammatory Lesions as Detected by MRI. Amendment 4: 1-Year Extension of Study Unknown status NCT00844142 Phase 2 Etanercept 25mg;Sulfasalazine
152 Randomized, Placebo Controlled Double Blind, Multi-center Phase II Proof-of-concept Study to Assess the Efficacy of AIN457 in Patients With Moderate to Severe Ankylosing Spondylitis Completed NCT00809159 Phase 2 Placebo
153 A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis Completed NCT02963506 Phase 2 Bimekizumab
154 A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis Completed NCT02201043 Phase 2 Thalidomide 150mg;Thalidomide 100mg;Placebo
155 International Multi-center Comparative Randomized Double-blind Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Active Ankylosing Spondylitis Completed NCT02763111 Phase 2 BCD-085
156 Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis Completed NCT00004288 Phase 2 olsalazine
157 An Open Label Non-randomized Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti Interleukin-17 Monoclonal Antibody) in Patients With Moderate to Severe Ankylosing Spondylitis Completed NCT01109940 Phase 2
158 A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis. Completed NCT02047110 Phase 2 placebo for risankizumab;risankizumab
159 A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Efficacy and Safety of Filgotinib Administered for 12 Weeks to Subjects With Active Ankylosing Spondylitis Completed NCT03117270 Phase 2 filgotinib;Placebo Oral Tablet
160 A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (as) Completed NCT01786668 Phase 2 Tofacitinib 2 mg;Tofacitinib 5 mg;Tofacitinib 10 mg;Placebo
161 Efficacy and Safety of Risedronate (Actonel), a Third Generation Bisphosphonate in Patients With Ankylosing Spondylitis: a Phase 2 Pilot Study Completed NCT01038011 Phase 2 drug treatment
162 UsTekinumab for the Treatment Of Patients With Active Ankylosing Spondylitis (TOPAS) - a 28-week, Prospective, Open-label, Proof-of-concept Study Completed NCT01330901 Phase 2 Ustekinumab
163 A Randomized Double Blind-placebo Controlled Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 in Participants With Ankylosing Spondylitis (AS) Completed NCT01061723 Phase 2 Sarilumab;Placebo
164 Anti-Tumor Necrosis Factor (TNFR:Fc) in Ankylosing Spondylitis Completed NCT00000433 Phase 2 Anti-Tumor Necrosis Factor
165 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004)in the Treatment of Ankylosing Spondylitis (AS) Completed NCT00944658 Phase 2 Apremilast;Placebo (sugar pill)
166 The Effects of Oral Nanocurcumin on Expression Levels of microRNAs and Treg Cells and Th17 Cells Development Factors in Ankylosing Spondylitis Patients Completed NCT03140657 Phase 2 Nanocurcumin;Placebo
167 Web-based Support to Manage Arthritis Pain Completed NCT01463189 Phase 2
168 A Phase I/II Study of Repeat Intra-articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis Subjects With and Without Concurrent TNF-alpha Antagonists Completed NCT00126724 Phase 1, Phase 2
169 Prospective, Single-centre, Double-Blind, Randomised, Placebo-controlled Study Evaluating Efficacy of Adalimumab + Methotrextate Compared With Placebo + Methotrexate in Patients With Early Oligoarthritis (ADEOS) Completed NCT04154852 Phase 2 Adalimumab;Methotrexate;Placebo;Folic Acid
170 A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Infliximab in Subjects With Pemphigus Vulgaris Receiving Prednisone Completed NCT00283712 Phase 2 Infliximab
171 A Phase II Open Label Clinical Trial of Etanercept for the Treatment of Hidradenitis Suppurativa Completed NCT00107991 Phase 2 etanercept
172 A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study Evaluating the Safety and Efficacy of Treatment With Ustekinumab or Golimumab in Subjects With Chronic Sarcoidosis Completed NCT00955279 Phase 2 Placebo;Golimumab;Ustekinumab
173 A Pilot Trial of Intravenous Pamidronate for Low Back Pain Completed NCT01210599 Phase 1, Phase 2 Pamidronate
174 A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis Recruiting NCT03926195 Phase 2 Filgotinib;Placebo;Standard of Care
175 A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease Recruiting NCT03201445 Phase 2 Filgotinib;Placebo;Standard of Care
176 Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach Recruiting NCT01988506 Phase 2 Interleukin 2
177 Phase IIb, Randomised, Double-blind, Placebo-controlled, Multi-centre Trial of Infliximab With Transcriptomic Biomarker and Mechanism Evaluation in Patients With Acute Pancreatitis. Recruiting NCT03684278 Phase 2 Infusion of 5 mg/kg Infliximab;Infusion of 10 mg/kg Infliximab
178 An Open Label Trial of Celecoxib in the Treatment of Mild Thyroid Eye Disease Recruiting NCT02845336 Phase 2 Celecoxib;artificial tears
179 A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis Active, not recruiting NCT03355573 Phase 2 Bimekizumab
180 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis Active, not recruiting NCT03178487 Phase 2 Upadacitinib;Upadacitinib Placebo
181 A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects With Active Ankylosing Spondylitis Active, not recruiting NCT03215277 Phase 2 Bimekizumab;Certolizumab pegol
182 Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial) Active, not recruiting NCT02538341 Phase 2 Placebo
183 Efficacy of Tofacitinib in Reduction of Inflammation Detected on MRI in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement - a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Not yet recruiting NCT04062695 Phase 2 Tofacitinib 5 MG Oral Tablet [Xeljanz];Placebo oral tablet
184 Individualizing Anti-Inflammatory Medications for Adults With Axial Spondyloarthritis: A Series of N-of 1 Trials Not yet recruiting NCT04115098 Phase 2 Drug order 1;Drug order 2;Drug order 3;Drug order 4;Drug order 5;Drug order 6
185 A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate the Efficacy and Safety of Tildrakizumab in Subjects With Active Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis Terminated NCT02980705 Phase 2 SUNPG1622 I dose;Placebo dose
186 A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis Terminated NCT00811499 Phase 2 ARRY-371797, p38 inhibitor; oral;Placebo; oral;Placebo; oral
187 A Multicenter Uncontrolled Extension Study Evaluating the Long Term Safety and Efficacy of SAR153191 in Patients With Ankylosing Spondylitis (AS) Terminated NCT01118728 Phase 2 Sarilumab
188 A Double-Blind Randomized Placebo-Controlled Single and Multiple Ascending Doses Study of the Safety and Tolerability, Pharmacokinetics (Including Bioavailability Comparison and Food Effect) and Pharmacodynamics of Oral BMS-986251 Administration in Healthy Subjects, With Efficacy Assessment of Multiple Doses in Patients With Moderate-to-Severe Psoriasis Terminated NCT03329885 Phase 1, Phase 2 BMS-986251
189 Phase II Study of 99mTc-rhAnnexin V-128 Radionuclide Imaging in Patients With Clinical Suspicion or Confirmed Diagnosis of Spondyloarthritis (SpA) Terminated NCT03232580 Phase 2 rhAnnexin V-128
190 A Phase I-IIa Study of Safety, Tolerance, Pharmacokinetics, Dosimetry and Benefice of Early Nuclear Medicine Imaging of 99mTc-rhAnnexin V-128 in Patients With Rheumatoid Arthritis or Ankylosing Spondylitis Terminated NCT02328027 Phase 1, Phase 2 99mTc-rhAnnexin V-128
191 A Phase II, Multi-Center, Open Label Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis Withdrawn NCT00731757 Phase 2 Humira
192 Phase II Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat AS Unknown status NCT01420432 Phase 1
193 Safety and Efficacy Study of Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar Intervertebral Disc Degeneration Unknown status NCT02338271 Phase 1
194 Randomized, Double-blind, Parallel-group, Phase 1 Study Completed NCT01220518 Phase 1 Infliximab
195 An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1 Completed NCT01571206 Phase 1
196 International Multicenter Comparative Double Blind Study of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis Completed NCT02359903 Phase 1 Infliximab (BCD-055);Infliximab (Remicade)
197 An Ascending Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Gimsilumab in Healthy Subjects and Subjects With Ankylosing Spondylitis Completed NCT04205851 Phase 1 KIN-1901;Placebo
198 A Phase I, Randomized, Open-label, Parallel-group Study to Determine the Pharmacokinetics, Safety, and Tolerability of MSB11022 (Proposed Adalimumab Biosimilar) Following a Single Subcutaneous Injection by an Auto-injector or by a Pre-filled Syringe in Healthy Subjects Completed NCT04018599 Phase 1 40 mg MSB11022;40 mg MSB11022
199 A Pilot, Open-Label, Randomized, Crossover, Pharmacokinetic Study Of Enhanced Bioavailability Formulations Of Celecoxib In Healthy Volunteers Completed NCT00813241 Phase 1 celecoxib reference formulation;celecoxib test formulation A1;celecoxib test formulation B2;celecoxib test formulation C1
200 A Multicenter Postmarketing Study to Evaluate the Placental Transfer of Certolizumab Pegol in Pregnant Women Receiving Treatment With Cimzia® (Certolizumab Pegol) Completed NCT02019602 Phase 1
201 A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol) Completed NCT02154425 Phase 1
202 A Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis Completed NCT00617032 Phase 1
203 Multi-center, Randomized, Open-Label, 2-Arm Parallel Study to Compare the Pharmacokinetics, Safety and Tolerability of AVT02 Administered Subcutaneously Via Prefilled Syringe or Autoinjector in Healthy Adult Volunteers (ALVOPAD PEN) Completed NCT03983876 Phase 1 Adalimumab
204 Multicentre, Randomized, Double-Blind, 3-Arm, Parallel Study to Compare the Pharmacokinetics, Safety and Tolerability of AVT02 to EU-approved and US-licensed Humira® Administered as a Single Dose (40 mg Subcutaneous Injection) in Healthy Adult Volunteers (ALVOPA D FIRST) Active, not recruiting NCT03849313 Phase 1 Adalimumab
205 The Effect of Acupuncture Protocol Involving in Weizhong (BL4) and Huantiao (GB30) Points in Treating Ankylosing Spondylitis Unknown status NCT02260310
206 A Multicenter Registry to Evaluate the Clinical Outcome of Chinese Adult Patients With Active Ankylosing Spondylitis Treated With Adalimumab in the Real World Practice Unknown status NCT01901627
207 Application of Dynamic Contrast Enhanced MRI in Clinical and Early Diagnosis of Brucellar Spondylitis Unknown status NCT02809625
208 Is the Human Microbiome Altered in Patients With Axial Spondyloarthritis? Unknown status NCT02962479
209 Assessment of the Efficacy of a Physical Training Program in Patients With Ankylosing Spondylitis Unknown status NCT02284646
210 An Open Label Extension, Investigator Initiated Trial to Examine Radiographic Progression , Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis. EASIC (European Ankylosing Spondylitis Infliximab Cohort) Unknown status NCT00237419 infliximab
211 The Effect of Acupuncture in Treating Chronic Low-back Pain Unknown status NCT02260284
212 Non-infectious and Infectious Uveitis Diagnosis Unknown status NCT02627209
213 Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy Unknown status NCT00517101
214 The RATIO Registry: French Registry on Opportunistic and Severe Bacterial Infections and Lymphoma in Patients Treated With TNF-a Antagonists Unknown status NCT00224562 TNF-alpha antagonists
215 Evaluation of the Expression and Functions of the KIR3DL2 Receptor and the Anti-inflammatory Activity of IPH4102 (Monoclonal Antibody IPH4102 Targeting KIR3DL2) in Blood Samples Taken From Patients With Axial Spondyloarthritis and Healthy Volunteers Unknown status NCT03322618
216 Rheumatological Manifestations in Inflammatory Bowel Diseases Unknown status NCT03486652
217 Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan Unknown status NCT00747578
218 Prevalence of Antiphospholipid Antibodies in Ankylosing Spondylitis: A Study of 80 Patients Unknown status NCT02809300
219 European Ankylosing Spondylitis Infliximab Cohort (EASIC) Follow up Registration Study Unknown status NCT01286545
220 Frequency of Axial Spondyloarthropathy Among Patients Suffering From Fibromyalgia - Application of the ASAS Classification Criteria Unknown status NCT01167413
221 Evaluation of the Usefulness of Interferon-γ Release Assays and Tuberculin Skin Test for Detection of Latent Mycobacterium Tuberculosis Infection in Korean Patients With Rheumatic Diseases Unknown status NCT01685905
222 Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis Unknown status NCT02922192 TNF-α antagonists, non-TNFs, DMARD non-biologics
223 Does Immunogenicity Have an Influence on the Efficacy of Anti-tumor Necrosis Factor (Anti-TNF) Therapy in Patients With Ankylosing Spondylitis (AS): An Inception Cohort Study Unknown status NCT02687620
224 Protection of Autonomic Nervous System During Lower Spine Surgical Procedures: A Safety and Feasibility Study Unknown status NCT02873182
225 Assessment of Central Pain in Patients Who Undergo Spinal Surgery and Influence in Surgery Outcome Unknown status NCT01299818
226 Evaluation of an Outpatient Pharmacy Clinical Services Program on Adherence and Clinical Outcomes Among Patients With Rheumatic Diseases Unknown status NCT03024307
227 RxIALTA: Pharmacist CVD Intervention for Patients With Inflammatory Arthritis Unknown status NCT03152396
228 The Rehabilitation Outcome of Patients With Lumbar Spondylolisthesis. A Prospective Randomized Study Unknown status NCT02435485
229 Prospective, International, Multi-centre Study on ASAS Classification Criteria for SpA Unknown status NCT00328068
230 Observative and Community Study, Using Nailfold Video-capillaroscopy in Order to Assess the Prevalence of Pathological Changes in the Capillaries in First Grade Family Members of Patient Diagnosed With Systemic Sclerosis Unknown status NCT02795221
231 WEB-Based Physiotherapy for People With Axial Spondyloarthritis: A Cohort Study Unknown status NCT02666313
232 The Diagnostic Performance of Skeletal 99mTc-MDP SPECT/CT in Patients With Low Back Pain Unknown status NCT03298854
233 The Identification of Prognostic Indicators for Exercise Therapy in Patients With Nonspecific Chronic Low Back Pain: A Multicenter Trial Unknown status NCT02063503
234 Conditioning Based Intervention Strategies - ConBIS. A Research Study on the Potential of Remote Conditioning for Activation of Endogenous Organ Protection and the Underlying Molecular Mechanisms Unknown status NCT03380663
235 Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis (Complete - AS) Completed NCT01387802
236 Assial - Anti Tnf Treatment In Ankylosing Spondylitis: An Observational Cohort Study In Italy Completed NCT01856569
237 A Self-Administered Questionnaire for Early Detection of Axial Spondyloarthritis Completed NCT01302730
238 Work Productivity In A Cohort Of Employed Ankylosing Spondylitis Patients Treated With Etanercept Completed NCT01421303 Enbrel
239 Special Investigation (All Cases Investigation in Patients With Ankylosing Spondylitis) Completed NCT01329380
240 Observational Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis Completed NCT00227227
241 Australian Descriptive Epidemiology Study of Severity of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) and Exposure to Biological Disease Modifying Anti-rheumatic Drugs (bDMARDs) Completed NCT00751387
242 Ultrasound of Enthesis in Patients With Ankylosing Spondylitis: a Comparative Study With Health Subjects Completed NCT01567878
243 A Drug Use Investigation of Enbrel for Post-marketing Surveillance (PMS) for Ankylosing Spondylitis Completed NCT00195416 Etanercept
244 Remicade Therapy in Ankylosing Spondylitis: Investigation of Real Life Regimen in Austria Over 9 Consecutive Infusions Completed NCT00725543
245 Prevalence Study of Gastrointestinal Risk Factors in Patients With Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis Receiving Treatment With Non- Steroidal Anti- Inflammatory Drugs. Completed NCT01577563
246 Prospective, Multi-Center, Observational, Program to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation Completed NCT02988674
247 Remicade in the Treatment of Patients With Active Ankylosing Spondylitis Completed NCT01850121 Infliximab
248 Assessment of Effectiveness of Resistance Training Exercise Using the Swiss Ball in Patients With Ankylosing Spondylitis Completed NCT01351311
249 Observational Non-Interventional Study With Enbrel in Patients With Ankylosing Spondylitis Completed NCT01188655 Enbrel
250 Safety and Effectiveness of Adalimumab in Patients With Ankylosing Spondylitis in Routine Clinical Practice Completed NCT01079182
251 Cross-sectional, Observational Real Life Study on NSAIDs Treated Patients With Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis: Assessment of Patient Adherence to PPI Treatment Completed NCT01519375
252 A Prospective, Mono-Country, Multi-Center Study to Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis Patients on Adalimumab Therapy Completed NCT02333383 Adalimumab
253 A Five Year, Post-marketing Observational Study to Follow-up Patients With Rheumatoid Arthritis or Psoriatic Arthritis Who Are Treated With HUMIRA (Adalimumab) Completed NCT01078558
254 Remicade Safety Line (Ankylosing Spondylitis) Completed NCT00818168
255 Observational Study Of The Use Of Enbrel (Registered) (Etanercept) In Routine Clinical Practice To Treat Ankylosing Spondylitis (as) Patients: An Effectiveness, Safety, And Health Economic Evaluation Completed NCT00544557 Etanercept
256 European Real Life Study on NSAIDs Treated Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS): Assessment of Pain Relieve, Gastrointestinal (GI) Symptoms, Adherence and Health Resource Consumption Completed NCT01176682
257 Non-Interventional Study Investigating the Use of Golimumab (Simponi®) in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis Completed NCT01313858 Simponi®;Methotrexate
258 Tracking Biologics Along the Silk Road Completed NCT03006198
259 Increasing Physical Activity in Ankylosing Spondylitis (INPACT-AS): a Randomised Controlled Trial Completed NCT02374502
260 Multicountry Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab in Patients With Ankylosing Spondylitis and Psoriatic Arthritis Completed NCT01474876
261 Evaluation of a Patient Education Program for Ankylosing Spondylitis Completed NCT00722514
262 A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis Completed NCT01709656 "celecoxib", "Celebrex®"
263 Effect of Biological Disease Modifying Anti Rheumatic Drug (bDMARD) Treatment on Spinal Fracture Incidence in Patients With Ankylosing Spondylitis (AS) Completed NCT02840695 bDMARD treatment
264 Family Studies of the Genetics of Ankylosing Spondylitis Completed NCT00081562
265 Evaluation of Functions of Swallowing and Voice in Ankylosing Spondylitis Patients Completed NCT04437394
266 Post Marketing Surveillance of Remicade in Inflammatory Bowel Disease (IBD) Completed NCT00724529
267 Etoricoxib Prescribing Patterns and Adverse Events of Interest During Etoricoxib Treatment in UK Primary Care; an Updated Analysis Completed NCT01685424 Etoricoxib
268 Alexithymia in Ankylosing Spondylitis Completed NCT04320459
269 The Prevalence and the Progression of Periodontitis in Ankylosing Spondylitis (AS) Patients Versus Non-AS Population Completed NCT01750528
270 FUNCTIONAL LIMITATIONS DUE TO the FOOT INVOLVEMENT IN SPONDYLOARTHRITIS Completed NCT01833468
271 Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in RA and Spondyloarthritis Patients, Treated With TNFalpha-inhibitors in Combination With Methotrexate or Methotrexate or TNFalpha-inhibitors Alone - a Prospective Study Completed NCT00902005
272 Evaluation of Ovarian Reserve Using Anti-müllerian Hormone and Antral Follicle Count in Ankylosing Spondylitis: Preliminary Study Completed NCT04209881
273 Investigating the Effectiveness of Clinical Pilates Exercise When Applied Together With Aerobic Exercise in Patients With Ankylosing Spondylitis Completed NCT03211559
274 A Nested Case-control Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in a Cohort of Patients With Ankylosing Spondylitis (AS) in the UK, France and Germany Completed NCT01077843 Etoricoxib;Other Cox-2 inhibitors;Other Non-selective NSAIDs
275 Effect of Two Exercise Therapy Program With and Without Elastic Resistance in Ankylosing Spondylitis Patients Completed NCT01690273
276 Success and Failure of Biological Therapy: Predictors of Response in Patients With Active Ankylosing Spondylitis Completed NCT00900796
277 The Effects of Clinical Pilates Training on Disease-specific Indices, Core Stability, and Balance in Patients With Ankylosing Spondylitis Completed NCT04292028
278 Electroacupuncture for Relieving Pain in Ankylosing Spondylitis: a Single-arm Pilot Study Completed NCT02697968
279 The Relationship Between Bone Mineral Density, Disease Duration, and Activity in Patients With Ankylosing Spondylitis Completed NCT03866135
280 Genetic Determinants of Ankylosing Spondylitis Severity - Cross Sectional Study Completed NCT00056849
281 The Effect of Stretching Exercises in Water and on Land on Spinal Mobility and Functional Level in Patients With Ankylosing Spondylitis Completed NCT03667625
282 Impact of Adalimumab (Humira®) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice Completed NCT01754727
283 A Study on Quality of Life in Patients With Chronic Arthritis Completed NCT01357018
284 An Open Label Multicenter Post Marketing Observational Study for the Evaluation of Quality of Life Outcomes and Tolerability of HUMIRA in Routine Clinical Use in Patients With RA PsA AS After Unsustainable Response to Disease Modifying Antirheumatic Drugs and or Biologicals Completed NCT01083693
285 Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice Completed NCT01768858 Adalimumab
286 Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab Completed NCT01273519
287 Safety Data on Etoricoxib From Swedish Registries of Spondyloarthropathy/Ankylosing Spondylitis Patients Completed NCT01327638 etoricoxib;Other COX-2 inhibitor;nsNSAIDs
288 Observational Study in AS and PsA Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium Completed NCT01845818
289 Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity: a Randomized Controlled Trial Completed NCT01610947 Adalimumab, Etanercept, Golimumab or infliximab;Adalimumab, Etanercept, Golimumab or infliximab
290 Post-marketing Prospective, Observational Cohort Study to Evaluate the Impact of AbbVie Care Patient Support Program on Compliance With Adalimumab, Patient Reported Outcomes and Health Resource Utilization in Inflammatory Bowel Diseases, Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis and Psoriasis in Portugal Completed NCT03223012
291 Post Marketing Surveillance of Remicade in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Patients Completed NCT00760669 Infliximab; observational study;Methotrexate; observational study
292 Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study Completed NCT00056719
293 A Noninterventional Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Practice Completed NCT02354105
294 Defining Which Remission Criterion At Month 6 Predicts Remission At Month 12 In A Real Life Clinical Practice, In A Cohort Of Ankylosing Spondylitis Patients Treated With Etanercept (Enbrel (Registered)) Completed NCT02202850 etanercept;etanercept
295 Uveitis Gene-Expression Profiling Completed NCT00874471
296 A 2-year HRQL Observational Study Evaluating the Effect of Treatment With Adalimumab on Work Productivity and Sleep in Patients With Rheumatic Diseases in Greece Completed NCT01282372
297 European Study in Patients With Osteoarthritis, Rheumatoid Arthritis, or Ankylosing Spondylitis at Gastrointestinal Risk: A Retrospective, Non-interventional Study of Vimovo™ Prescribing Patterns Completed NCT01511926
298 Biopsychosocial Exploration of Pain Profiles in Inflammatory and Chronic Non-specific Axial Low Back Pain: An Exploration of Similarities and Differences Completed NCT02704845
299 Effect Of Anti TNF Alpha Therapy On Disease Activity And Bone Health, And Their Adverse Effects In Ankylosing Spondylitis In A North Indian Population Completed NCT01361542 anti TNF alpha agent;Anti TNF alpha therapy
300 Treatment With Alendronate in Patients With Ankylosing Spondylitis (AS), an Open Label Prospective Trial Completed NCT01104987 alendronate
301 A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis Treated With Golimumab and Other Types of Biological and Systemic Non Biological Treatments Completed NCT01081717 systemic non-biological treatments
302 Research Asistant in Deparment of Nursing Completed NCT04301128
303 A Multi-Center Post Marketing Observational Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed HUMIRA® (Adalimumab) as Part of Routine Clinical Care in Russia Completed